Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JX-594 and Sorafenib in Hepatocellular Carcinoma
NCT01171651Phase 2Completed
- Sponsor
- Jennerex Therapeutics
- Start
- May 2009
- Primary completion
- Sep 2012
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vaccinia granulocyte-macrophage colony-stimulating factor recombinant virus in hepatocellular carcinoma (HCC), sponsored by Jennerex Therapeutics. Primary endpoints: Incidence of treatment-related Grade 3 and Grade 4 adverse events and Incidence of treatment-related serious adverse events. Started May 2009; status: completed.
02
Drugs
vaccinia granulocyte-macrophage colony-stimulating factor recombinant virus
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT01171651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01171651.